"This study evaluates the interplay between lactose intolerance, intestinal barrier function (zonulin), and intestinal inflammation (fecal calprotectin) in adults, aiming to clarify their independent contributions to symptom severity and quality of life."
Eligibility
Sex
ALL
Min age
18 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria:
* Adults aged 18-70 years; experiencing chronic symptoms (diarrhea, bloating, abdominal pain, constipation, flatulence) for the past 3 months, potentially fitting IBS criteria.
Exclusion Criteria:
\- Acute gastroenteritis (\< 4 weeks), Active gastrointestinal bleeding (stomach, small intestine, and colon), Known celiac disease, Bariatric surgery or short bowel syndrome, Pregnancy or lactation, Type I and II Diabetes mellitus, Antibiotic use within the last 2 weeks, High-dose NSAIDs within the last 2 weeks, Initiation of probiotics or prebiotics within the last 4 weeks, High-dose PPI use (optional), Inflammatory bowel disease (IBD; ulceretive colitis and Crohn's colitis) with active severe flare (excluded from primary analyses, evaluated separately in subgroup analyses)
Primary outcome measure(s)
To determine the relationship between lactose intolerance (LI) and fecal biomarkers, zonulin (Z) and fecal calprotectin (FC), in adults with IBS. — Baseline assessment (single time point measurement of biomarkers and symptoms) The primary outcome of this study is to evaluate the relationship between lactose intolerance (LI) and fecal biomarkers-Z (as mg/kg), a marker of intestinal permeability (IP), and fecal calprotectin (FC) (as mg/kg), a marker of intestinal inflammation-in adults with irritable bowel syndrome (IBS). This includes assessing whether levels of these biomarkers are associated with the presence of LI and the severity of gastrointestinal symptoms related to lactose ingestion. The analysis aims to clarify how intestinal barrier function (Z) and inflammation (FC) contribute individually and jointly to symptom manifestation in LI patients within the IBS population.
Trial sites (1)
Facility
City
Region
Status
Bezmialem Vakıf University Medical Faculty Hospital
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.